ADC Therapeutics S.A.
ADC Therapeutics S.A. (ADCT) Revenue
Annual & quarterly revenue history · segment & region breakdown
ADCT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsADC Therapeutics S.A. trailing twelve-month (TTM) revenue is $0.08B, an increase of 14.85% year-over-year from $0.08B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.08B | +$0.01B | +14.85% |
| 2024-12-31 | $0.07B | +$0.00B | +1.84% |
| 2023-12-31 | $0.07B | -$0.14B | -66.86% |
| 2022-12-31 | $0.21B | +$0.18B | +518.89% |
| 2021-12-31 | $0.03B | +$0.03B | — |
| 2020-12-31 | $0.00B | -$0.00B | -100.00% |
| 2019-12-31 | $0.00B | +$0.00B | +105.26% |
| 2018-12-31 | $0.00B | -$0.00B | -36.77% |
| 2017-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare ADCT revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ADC Therapeutics S.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ADC Therapeutics S.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ADC Therapeutics S.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ADCT revenue · 4 questionsADCT's trailing twelve-month (TTM) revenue is $0.08B. That is an increase of 14.85% year-over-year from $0.08B in FY2025.
▸ Source: FMP · ADC Therapeutics S.A. SEC filings · GAAP · ADC Therapeutics S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026